Share this article

 Email

 Print

 

Republish this article

The text of this article by Futurity is licensed under a Creative Commons Attribution-No Derivatives License.

More
Health & Medicine

Dyslexia: Not the only reading disorder

After lung transplant, diabetes ups death risk

Facebook status boosts organ donors

Gene makes heart stronger without exercise

Tough guts of female mice point to colitis

To protect jockeys, protect horses first

Block nerve ‘sprouts’ to ease arthritis pain

Paid sick days would slow down flu at work

Lower risk of hypertension for seniors who volunteer

The work, reported in Science Translational Medicine, shows how the “hitchhiking” virus is shielded from antibodies in the blood stream that might otherwise neutralize its anti-cancer properties.

The findings suggest that therapies like this can be effectively injected into the bloodstream during routine outpatient appointments—just like standard chemotherapy—making them potentially suitable for use against a wide range of cancers.

In tests on a small group of patients, not only did the virus stay active during its journey through the bloodstream but it also homed in on cancer cells, ignoring nearby healthy tissue. (Credit: U. Leeds)

Reovirus is a promising new way of treating cancer that attacks the disease on two fronts. Not only does the virus kill cancer cells directly, but it also triggers an immune response—like a vaccine—that helps eliminate residual cancer cells.

Many patient trials of reovirus are currently under way. Up until now, however, doctors have not been sure about the best way to deliver the experimental treatment.  Although the virus can be injected directly into tumors, it’s a relatively complicated procedure requiring considerable technical expertise and also makes it difficult to treat tumors deep within the body, such as the liver, lungs, pancreas, and stomach.

Researchers had been concerned that reovirus might not reach the tumors it was supposed to treat if it was delivered intravenously, like standard chemotherapy agents are. They had expected that antibodies in the blood would mop up and neutralize the virus before it arrived at its intended target.

But now tests on a small group of patients have shown that this is not the case. In fact, not only did the virus stay active during its journey through the bloodstream but it also homed in on cancer cells, ignoring nearby healthy tissue.

“It seems that reovirus is even cleverer than we had thought. By piggybacking on blood cells, the virus is managing to hide from the body’s natural immune response and reach its target intact. This could be hugely significant for the uptake of viral therapies like this in clinical practice,” says University of Leeds researcher Professor Alan Melcher, who jointly led the study with Kevin Harrington from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

“Viral treatments like reovirus are showing real promise in patient trials. This study gives us the very good news that it should be possible to deliver these treatments with a simple injection into the bloodstream,” Harrington says.

“It would have been a significant barrier to their widespread use if they could only have been injected into the tumor, but the finding that they can hitch a ride on blood cells will potentially make them relevant to a broad range of cancers.

“We also confirmed that reovirus was specifically targeting cancer cells and leaving normal cells alone, which we hope should mean fewer side-effects for patients.”

The study involved 10 patients with advanced bowel cancer who were due to have surgery on tumors that had spread to the liver. All patients were given up to five doses of the reovirus in the weeks before surgery as outpatients.

Blood tests carried out shortly after treatment found the active virus associated with blood cells.  Samples taken later showed that the hitchhiking virus did not overstay its welcome with the cells and was cleared quickly from the system.

When researchers looked at pieces of tissue removed during surgery up to four weeks later, they found “viral factories” and active virus in the tumor, but not normal liver. This confirmed that the reovirus had been delivered specifically to the cancer after being injected into the bloodstream.

Julie Sharp, senior science information manager at Cancer Research UK, which partly funded the research, says: “This promising study shows that reovirus can trick the body’s defenses to reach and kill cancer cells and suggests that it could be given to patients using a simple injection. We look forward to seeing how this research develops and if this could one day become part of standard cancer treatment.”

The work was funded by Cancer Research UK, Leeds Experimental Cancer Medicine Centre, University of Leeds, The Institute of Cancer Research, Leeds Cancer Vaccine Appeal, and the Rays of Hope Appeal.

More news from University of Leeds: www.leeds.ac.uk/news